OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
September 29, 2022
FDA is highlighting how the Patient-Focused Drug Development program has encouraged active involvement of many patient groups in bringing their perspectives into the process of developing, testing, and approving new medicines.
September 28, 2022
A combination of eye imaging techniques and adaptive optics has revealed key details of choroideremia.
The dedicated solid-state research and development suite is designed to promote discovery of novel polymorph, salt, and cocrystal forms.
September 27, 2022
Roquette’s acquisition of Crest Cellulose is designed to reinforce its presence in India and other countries in Asia.
September 20, 2022
CytoReason has announced an expanded collaboration deal with Pfizer to deliver AI for drug discovery and development.
Experts from Umoja Biopharma dive into cell therapy development in this episode of the Drug Solutions Podcast, including the greatest advancements in cell therapy to date, areas for improvement, the biggest trends in cell therapy development, and retention as a pain point.
September 19, 2022
Novo Nordisk and Microsoft are collaborating to accelerate drug discovery and development using big data and artificial intelligence.
Ensysce Biosciences and Quotient Sciences are partnering to develop and test Ensysce’s novel opioid designed to prevent abuse and overdose.
September 16, 2022
Automation enables intensification of downstream processes.
September 06, 2022
How Pfizer’s external-facing research and development scientists uncover the most promising emerging therapy concepts and ideas in the pharmaceutical landscape.